The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Impact of mutant p53 functional properties on <i>TP53</i> mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · see citing works

Cytoplasmic functions of the tumour suppressor p53

Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · see citing works

The MDM2-p53 interaction.

Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 778 · see citing works

Gastrosplenic Fistula From Hodgkin's Lymphoma

Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 736 · see citing works

The genetics of the p53 pathway, apoptosis and cancer therapy

Vázquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 674 · see citing works

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

Laı́n, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A. R., Appleyard, V. C. L., Murray, K. E., Baker, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.004 · Cited by 523 · see citing works

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

Kojima, K., Konopleva, M. Y., Samudio, I. J., Shikami, M., Cabreira-Hansen, M. D. G., McQueen, T. J., Ruvolo, V. R., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407 · see citing works

In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation

Erster, S. H., Mihara, M., Kim, R. H., Petrenko, O., & Moll, U. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6728-6741.2004 · Cited by 367 · see citing works

Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation

Strom, E., Sathe, S. S., Komarov, P. G., Chernova, O. B., Pavlovska, I., Shyshynova, I., Bosykh, D. A., Burdelya, L. G., Macklis, R. M., Skaliter, R., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio809 · Cited by 327 · see citing works

Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis

Hershko, T., & Ginsberg, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312866200 · Cited by 322 · see citing works

The human MDM-2 oncogene is overexpressed in leukemias

Bueso-Ramos, C., Yang, Y. S., deLeon, E., McCown, P., Stass, S. A., & Albitar, M. X. (1993) · Blood · doi:10.1182/blood.v82.9.2617.bloodjournal8292617 · Cited by 292 · see citing works

Differential regulation of E2F1 apoptotic target genes in response to DNA damage

Pediconi, N., Ianari, A., Costanzo, A., Belloni, L., Gallo, R., Cimino, L., Porcellini, A., Screpanti, I., Balsano, C., Alesse, E., et al. (2003) · Nature Cell Biology · doi:10.1038/ncb998 · Cited by 266 · see citing works

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

Kojima, K., Konopleva, M. Y., McQueen, T. J., O'Brien, S. M., Plunkett, W. K., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2005-12-5148 · Cited by 250 · see citing works

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

Enge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 170 · see citing works

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163 · see citing works

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)

Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4465 · Cited by 157 · see citing works

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway

Zhang, Z., Wang, H., Li, M., Rayburn, E. R., Agrawal, S., & Zhang, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208814 · Cited by 139 · see citing works

Targeting p53 for enhanced radio- and chemo-sensitivity

Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 137 · see citing works

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F

Hiyama, H., Iavarone, A., & Reeves, S. A. (1998) · Oncogene · doi:10.1038/sj.onc.1201667 · Cited by 125 · see citing works

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

Kojima, K., Shimanuki, M., Shikami, M., Samudio, I. J., Ruvolo, V. R., Corn, P. G., Hanaoka, N., Konopleva, M. Y., Andreeff, M., & Nakakuma, H. (2008) · Leukemia · doi:10.1038/leu.2008.158 · Cited by 114 · see citing works

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

Gu, L., Zhu, N., Findley, H. W., & Zhou, M. L. (2008) · Leukemia · doi:10.1038/leu.2008.11 · Cited by 112 · see citing works

Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F

Hershko, T., Chaussepied, M., Oren, M., & Ginsberg, D. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401575 · Cited by 107 · see citing works

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 99 · see citing works

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

Kitagawa, M., Aonuma, M., Lee, S. H., Fukutake, S., & McCormick, F. P. (2008) · Oncogene · doi:10.1038/onc.2008.164 · Cited by 88 · see citing works

The transcription-independent mitochondrial p53 program is a major contributor to Nutlin-induced apoptosis in tumor cells

Vaseva, A. V., Marchenko, N. D., & Moll, U. M. (2009) · Cell Cycle · doi:10.4161/cc.8.11.8596 · Cited by 88 · see citing works

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

Secchiero, P., Melloni, E., di Iasio, M. G., Tiribelli, M., Rimondi, E., Corallini, F., Gattei, V., & Zauli, G. (2009) · Blood · doi:10.1182/blood-2008-11-187708 · Cited by 83 · see citing works

30 years and a long way into p53 research

Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 75 · see citing works

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism

Steele, A. J., Prentice, A. G., Hoffbrand, A. V., Yogashangary, B. C., Hart, S., Nacheva, E. P., Howard‐Reeves, J., Duke, V. M., Kottaridis, P. D., Cwynarski, K., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156380 · Cited by 69 · see citing works

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML

Carter, B. Z., Mak, D. H. F., Schober, W. D., Koller, E., Pinilla, C., Vassilev, L. T., Reed, J. C., & Andreeff, M. (2009) · Blood · doi:10.1182/blood-2009-03-212563 · Cited by 67 · see citing works

The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73

Peirce (2009) · International Journal of Oncology · doi:10.3892/ijo_00000267 · Cited by 67 · see citing works

Mutated and non‐mutated TP53 as targets in the treatment of leukaemia

Nahi, H., Selivanova, G., Lehmann, S., Möllgård, L., Bengtzén, S., Concha, H., Svensson, A., Wiman, K. G., Merup, M., & Paul, C. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07046.x · Cited by 58 · see citing works

HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target

Han, X., Garcia‐Manero, G., McDonnell, T. J., Lozano, G., Medeiros, L. J., Xiao, L., Rosner, G. L., Nguyen, M. H., Fernandez, M., Valentin-Vega, Y. A., et al. (2006) · Modern Pathology · doi:10.1038/modpathol.3800727 · Cited by 45 · see citing works

The MDM2-Binding Region in the Transactivation Domain of p53 Also Acts as a Bcl-X L -Binding Motif

Xu, H., Hong, Y., Osman, N. E., Sadler, K. E., Won, E.-Y., Chi, S., & Yoon, H. S. (2009) · Biochemistry · doi:10.1021/bi901188s · Cited by 33 · see citing works

Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia

Volanakis, E. J., Williams, R. T., & Sherr, C. J. (2009) · Blood · doi:10.1182/blood-2009-07-233346 · Cited by 25 · see citing works

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors

Tabernero, J. M., Dirix, L. Y., Schöffski, P., Cervantes, A. M. R., Capdevila, J., Baselga, J. M., van Beijsterveldt, L., Winkler, H. J. S., Kraljevic, S., & Zhuang, S. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3514 · Cited by 18 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

The Roles of MDM2 and MDMX in Cancer

Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 293 · see citing works

p53 Family and Cellular Stress Responses in Cancer

Pflaum, J., Schlosser, S., & ller, M. M. ⁄. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 294 · see citing works

Role of p53 in breast cancer progression: An insight into p53 targeted therapy

Marvalim, C., Datta, A., & Lee, S. C. (2023) · Theranostics · doi:10.7150/thno.81847 · Cited by 243 · see citing works

p53 as a target for the treatment of cancer

Duffy, M. J., Synnott, N. C., McGowan, P. M., Crown, J. P., O’Connor, D. P., & Gallagher, W. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.004 · Cited by 230 · see citing works

Protein-protein interaction modulators: advances, successes and remaining challenges

Mabonga, L., & Kappo, A. P. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00570-x · Cited by 196 · see citing works

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 192 · see citing works

Small‐Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System

Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 153 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 156 · see citing works

Small‐molecule protein–protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations

Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133 · see citing works

MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension

Shen, H., Zhang, J., Wang, C., Jain, P., Xiong, M., Shi, X., Lei, Y., Chen, S., Yin, Q., Thistlethwaite, P. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048191 · Cited by 127 · see citing works

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

Yuan, Y., Liao, Y.-M., Hsueh, C.-T., & Mirshahidi, H. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-16 · Cited by 118 · see citing works

Targeting p53 by small molecules in hematological malignancies

Saha, M. N., Qiu, L., & Chang, H. H. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-23 · Cited by 112 · see citing works

Targeting p53-MDM2-MDMX Loop for Cancer Therapy

Zhang, Q., Zeng, S. X., & Lu, H. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_16 · Cited by 85 · see citing works

Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions

Bojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 81 · see citing works

Reviving the guardian of the genome: Small molecule activators of p53

Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 83 · see citing works

p28, A first in class peptide inhibitor of cop1 binding to p53

Yamada, T., Christov, K. T., Shilkaitis, A. L., Bratescu, L., Green, A., Santini, S., Bizzarri, A. R., Cannistraro, S., Gupta, T. K. D., & Beattie, C. W. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.266 · Cited by 78 · see citing works

Translational approaches targeting the p53 pathway for anti‐cancer therapy

Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77 · see citing works

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma

Lakoma, A., Barbieri, E., Agarwal, S., Jackson, J. R., Chen, Z., Kim, Y., McVay, M. C., Shohet, J. M., & Kim, E. S. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.26 · Cited by 77 · see citing works

Targeting Mutant p53 in Human Tumors

Lehmann, B. D., & Pietenpol, J. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0412 · Cited by 72 · see citing works

Targeting the ubiquitin proteasome system in haematological malignancies

Crawford, L., & Irvine, A. E. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.10.002 · Cited by 72 · see citing works

Wild type p53 reactivation: From lab bench to clinic

Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 65 · see citing works

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

VOON, Y.-L., Wong, P., & Khoo, A. S. B. (2017) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170717125821 · Cited by 66 · see citing works

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

Tabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1101 · Cited by 64 · see citing works

Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 65 · see citing works

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R. G., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24235 · Cited by 64 · see citing works

Role of de novo cholesterol synthesis enzymes in cancer

Yang, J., Wang, L., & Jia, R. (2020) · Journal of Cancer · doi:10.7150/jca.38598 · Cited by 63 · see citing works

Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation

Qin, J., Wang, W., Voruganti, S., Wang, H., Zhang, W., & Zhang, R. (2014) · Oncotarget · doi:10.18632/oncotarget.3098 · Cited by 56 · see citing works

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts

Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J., & Deutsch, E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.011 · Cited by 54 · see citing works

Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer

Guo, T., Dong, X., Xie, S., Zhang, L., Zeng, P., & Zhang, L. (2021) · Cancer Management and Research · doi:10.2147/cmar.s292992 · Cited by 54 · see citing works

Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer

Sarkar, A., Paul, A., Banerjee, T., Maji, A., Saha, S., Bishayee, A., & Maity, T. K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175588 · Cited by 47 · see citing works

Protein–protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays

Gul, S., & Hadian, K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.954544 · Cited by 46 · see citing works

Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies

Wu, J., Kumar, S., Wang, F., Wang, H., Chen, L., Arsenault, P., Mattern, M. R., & Weinstock, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00498 · Cited by 47 · see citing works

Potential therapeutic targets ofTP53gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer

Tanaka, T., Watanabe, M., & Yamashita, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24611 · Cited by 46 · see citing works

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

Sosin, A. M., Burger, A. M., Siddiqi, A., Abrams, J., Mohammad, R. M., & Al-Katib, A. M. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-57 · Cited by 40 · see citing works

Pharmacological Activation of p53 in Cancer Cells

Athar, M., Elmets, C. A., & Kopelovich, L. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222595 · Cited by 38 · see citing works

Lymphomas driven by Epstein–Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2

Alqarni, S. S., Al‐Sheikh, Y. A., Campbell, D., Drotar, M. E., Hannigan, A., Boyle, S., Herzyk, P., Kossenkov, A. V., Armfield, K., Jamieson, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0147-x · Cited by 37 · see citing works

Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition

Xolalpa, W., Pérez‐Galán, P., Rodríguez, M. S., & Roué, G. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319220014 · Cited by 29 · see citing works

Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to p53-MDM2 Interaction Inhibitors

Xue, X., Wei, J., Xu, L., Xi, M., Xu, X., Liu, F., Guo, X., Wang, L., Zhang, X., Zhang, M., et al. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400348f · Cited by 30 · see citing works

Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model

Carter, B. Z., Mak, P. Y., Mu, H. H., Wang, X., Tao, W., Mak, D. H. F., Dettman, E. J., Cardone, M. H., Zernovak, O., Seki, T., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219261 · Cited by 29 · see citing works

Recent Synthetic Approaches towards Small Molecule Reactivators of p53

Silva, J. L., Lima, C. G. S., Rangel, L. P., Ferretti, G. D. S., Pauli, F. P., Ribeiro, R. C. B., Silva, T. B., da Silva, F. D. C., & Ferreira, V. F. (2020) · Biomolecules · doi:10.3390/biom10040635 · Cited by 30 · see citing works

Role of Di-allyl Disulfide, a Garlic Component in NF-κB Mediated Transient G2-M Phase Arrest and Apoptosis in Human Leukemic Cell-lines

Dasgupta, P., & Sengupta, S. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.776090 · Cited by 27 · see citing works

The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1

Jones, R. J., Gu, D., Bjorklund, C. C., Kuiatse, I., Remaley, A. T., Bashir, T., Vreys, V., & Orlowski, R. Z. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204958 · Cited by 26 · see citing works

Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., Keir, S. T., Morton, C. L., Reynolds, C. P., Kang, M. H., et al. (2012) · Pediatric Blood &amp; Cancer · doi:10.1002/pbc.23319 · Cited by 26 · see citing works

Reactivation of p53 via MDM2 inhibition

Kim, E. S., & Shohet, J. M. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.302 · Cited by 21 · see citing works

Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis

Jiang, A., Bao, Y., Wang, A., Gong, W., Gan, X., Wang, J., Bao, Y., Wu, Z., Liu, B., Lü, J., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3617775 · Cited by 17 · see citing works

Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials

Strickland, S. A., Sun, Z., Ketterling, R. P., Cherry, A. M., Cripe, L. D., Dewald, G. W., Fernandez, H. F., Hicks, G. A., Higgins, R. R., Lazarus, H. M., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.05.010 · Cited by 18 · see citing works

Stereodivergent total synthesis of chlorofusin and its all seven chromophore diastereomers

Qiu, H., Qian, W., Yu, S., & Yao, Z. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.10.062 · Cited by 19 · see citing works

Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)

Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 16 · see citing works

Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia

Li, S., Wang, C., Wang, W., Liu, W., & Zhang, G. (2018) · Medicine · doi:10.1097/md.0000000000010734 · Cited by 16 · see citing works

Quinofuracins A–E, Produced by the Fungus Staphylotrichum boninense PF1444, Show p53-Dependent Growth Suppression

Tatsuda, D., Momose, I., Someno, T., Sawa, R., Kubota, Y., Iijima, M., Kunisada, T., Watanabe, T., Shibasaki, M., & Nomoto, A. (2015) · Journal of Natural Products · doi:10.1021/np500581m · Cited by 16 · see citing works

Serdemetan Antagonizes the Mdm2-HIF1α Axis Leading to Decreased Levels of Glycolytic Enzymes

Lehman, J. A., Hauck, P. M., Gendron, J. M., Batuello, C. N., Eitel, J. A., Albig, A. R., Kadakia, M., & Mayo, L. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074741 · Cited by 14 · see citing works

Mdm2 and MdmX Involvement in Human Cancer

Berberich, S. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_15 · Cited by 12 · see citing works

An Effective Virtual Screening Protocol To Identify Promising p53–MDM2 Inhibitors

Tortorella, P., Laghezza, A., Durante, M., Gomez-Monterrey, I. M., Bertamino, A., Campiglia, P., Loiodice, F., Daniele, S., Martini, C., & Agamennone, M. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00747 · Cited by 12 · see citing works

CLINICAL IMPLICATIONS OF p53 ALTERATIONS IN ORAL CANCER PROGRESSION: A REVIEW FROM INDIA

Patel, K. R., Vajaria, B. N., Singh, R., Begum, R., & Patel, P. S. (2018) · Experimental Oncology · doi:10.31768/2312-8852.2018.40(1):10-18 · Cited by 12 · see citing works

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins

You, L., Liu, H., Huang, J., Xie, W., Wei, J., Ye, X., & Qian, W. (2016) · Oncotarget · doi:10.18632/oncotarget.13951 · Cited by 11 · see citing works

Steuerung der intrazellulären Proteinmenge durch niedermolekulare Modulatoren des Ubiquitin‐Proteasom‐Systems

Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie · doi:10.1002/ange.201307761 · Cited by 11 · see citing works

Sulfonoquinovosyl diacylglyceride selectively targets acute lymphoblastic leukemia cells and exerts potent anti-leukemic effects in vivo

Jain, C. K., Pradhan, B. S., Banerjee, S., Mondal, N. B., Majumder, S. S., Bhattacharyya, M., Chakrabarti, S., Roychoudhury, S., & Majumder, H. K. (2015) · Scientific Reports · doi:10.1038/srep12082 · Cited by 11 · see citing works

New targeted approaches against the ubiquitin–proteasome system in gastrointestinal malignancies

Grande, E., Earl, J., Fuentes, R., & Carrato, A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.26 · Cited by 7 · see citing works

Apoptosis in Cancer

Siddik, Z. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00012-7 · Cited by 6 · see citing works

Identification of a p53-based portable degron based on the MDM2-p53 binding region

Melvin, A. T., Dumberger, L. D., Woss, G. S., Waters, M. L., & Allbritton, N. L. (2015) · The Analyst · doi:10.1039/c5an01429h · Cited by 7 · see citing works

MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7 · see citing works

Development of β-Hairpin Peptides for the Measurement of SCF-Family E3 Ligase Activity in Vitro via Ornithine Ubiquitination

Houston, K. M., Melvin, A. T., Woss, G. S., Fayer, E. L., Waters, M. L., & Allbritton, N. L. (2017) · ACS Omega · doi:10.1021/acsomega.7b00109 · Cited by 6 · see citing works

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

Pujals, A., Favre, L., Gaulard, P., & Wiels, J. (2015) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s60486 · Cited by 3 · see citing works

In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1

Kędzierski, J., Jäger, M.-C., Naeem, S., Odermatt, A., & Smieško, M. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116945 · Cited by 2 · see citing works

Ciblage pharmacologique de Mdm2 : bases biologiques et perspectives de radiosensibilisation

Chargari, C., Leteur, C., Ferté, C., Deberne, M., Lahon, B., Rivera, C., Bourhis, J., & Deutsch, É. (2011) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2011.02.003 · Cited by 2 · see citing works

p27 Cell Cycle Inhibitor and Survival in Luminal-Type Breast Cancer: Gene Ontology, Machine Learning, and Drug Screening Analysis

Park, I. A., Noh, Y., Min, K., Kim, D., Lee, J., Son, B. K., Kwon, M. J., Han, M., Hur, J. Y., & Pyo, J. (2024) · Journal of Breast Cancer · doi:10.4048/jbc.2024.0107 · Cited by 1 · see citing works

Targeting p53 Tumor Suppressor for AML Therapy

Kojima, K., & Vassilev, L. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_7 · Cited by 1 · see citing works

Proteasome Inhibitors Versus E3 Ligase Inhibitors for Cancer Therapy

Mattern, M. R., Eddins, M. J., Agarwal, S., Sterner, D. E., Kodrasov, M. P., Kumar, S., Wu, J., & Nicholson, B. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-06752-0_12 · Cited by 1 · see citing works

In Vitro Analysis of Protein:Protein Interactions in the Human Cancer-Pertinent rp.eL42-p53-Mdm2 Pathway

Aguida, B., Bouceba, T., Créchet, J., Hounguè, H., Capo‐chichi, C. D., Nakayama, J., Baouz, S., Pelczar, H., Woisard, A., Jourdan, N., et al. (2019) · The Open Biochemistry Journal · doi:10.2174/1874091x01913010064 · Cited by 1 · see citing works

“Global Transcriptional Response to CRISPR/CAS9-AAV6 Based Genome Editing” Matches Transcriptional Response to Specific Small Molecule PerturbationsPreprint

Nordor, A. V., Aryee, M. J., & Siwo, G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/399311 · Cited by 1 · see citing works

Hdm2 Small-Molecule Inhibitors For Therapeutic Intervention In B-Cell Lymphoma

Sosin, A. M. (2012) · Human Biology

Mutacje TP53 w nowotworach hematologicznych

Zajac, M., & Giannopoulos, K. (2015) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2015.11.005

A regulatory network of Mdm2 and members of the Polycomb Group (PcG) family

Wienken, M. M. (2016) · doi:10.53846/goediss-5475

Targeting MDM2, the antagonist of the tumor suppressor p53

Sriraman, A. (2018) · doi:10.53846/goediss-7056

TP53

Kojima, K., & Andreeff, M. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch36

Conception et évaluation de peptides inhibiteurs de l'interaction ribosomale hCINAP/RPS14 dans un but antitumoral

Duflocq, S. (2021) · theses.fr (ABES) · doi:10.70675/ef227c50z2ceez459dzb908z9a4d36e0af98

BindingDB Entry 50045771: Quinofuracins A-E, produced by the fungus Staphylotrichum boninense PF1444, show p53-dependent growth suppression.

BindingDB (2016) · UC San Diego · doi:10.7270/q25b046z

BindingDB Entry 50001159: Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.

BindingDB (2020) · UC San Diego · doi:10.7270/q2cr5wvg

Preclinical Development The Novel Tryptamine Derivative JNJ- Wild-Type p53- and E2F1-Mediated Ap

Myeloid, A., Leukem, L., Kojima, K., Burks, J. K., & Arts, J. (2016)

Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

Samudio, I. J., Duvvuri, S. R., Clise-Dwyer, K., Watt, J. C., Mak, D. H. F., Kantarjian, H. M., Yang, D., Ruvolo, V. R., & Borthakur, G. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003731325 · Cited by 14 · see citing works

A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo

Stühmer, T., Arts, J., King, P., Page, M., Bommert, K., Leo, E., & Bargou, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14694 · Cited by 7 · see citing works

Inhibition of p53-MDM2 Interaction by Small-Molecule Antagonist of MDM2 Effectively Induces Apoptosis in Leukemias.

Kojima, K., Konopleva, M. Y., Shikami, M., Cabreira-Hansen, M. D. G., Jackson, C. E., Shpall, E. J., Kornblau, S. M., Vassilev, L., & Andreeff, M. (2004) · Blood · doi:10.1182/blood.v104.11.2536.2536

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

Kojima, K., Konopleva, M. Y., Samudio, I. J., Shikami, M., Cabreira-Hansen, M. D. G., McQueen, T. J., Ruvolo, V. R., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407 · see citing works